INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Papayannidis C, Petracci E, Zappasodi P, Fracchiolla N, Ciceri F, Sartor C, Roncoroni E, Di Raimondo F, Mattei D, Giannini MB, Lanza F, Gottardi M, Del Principe MI, Borlenghi E, Fumagalli M, Vallisa D, Sica S, Di Renzo N, Fabbiano F, Todisco E, de Fabritiis P, Luppi M, Passamonti F, Corradini P, Petruzziello F, Pane F, Ferrara F, Mambelli G, Volpi R, Frabetti F, Zingaretti C, Marconi G, Martinelli G.
Papayannidis C, et al. Among authors: petruzziello f.
Cancer. 2025 Apr 1;131(7):e35820. doi: 10.1002/cncr.35820.
Cancer. 2025.
PMID: 40120068
Free PMC article.